Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1990 1
1991 1
1992 1
1993 1
1994 2
1995 2
1996 2
1997 1
1998 1
1999 2
2000 8
2001 6
2002 7
2003 9
2004 9
2005 6
2006 9
2007 6
2008 8
2009 7
2010 11
2011 4
2012 13
2013 9
2014 8
2015 6
2016 11
2017 8
2018 11
2019 7
2020 2
2021 5
2022 11
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

187 results

Results by year

Filters applied: . Clear all
Page 1
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
Rosiñol L, Beksac M, Zamagni E, Van de Donk NWCJ, Anderson KC, Badros A, Caers J, Cavo M, Dimopoulos MA, Dispenzieri A, Einsele H, Engelhardt M, Fernández de Larrea C, Gahrton G, Gay F, Hájek R, Hungria V, Jurczyszyn A, Kröger N, Kyle RA, Leal da Costa F, Leleu X, Lentzsch S, Mateos MV, Merlini G, Mohty M, Moreau P, Rasche L, Reece D, Sezer O, Sonneveld P, Usmani SZ, Vanderkerken K, Vesole DH, Waage A, Zweegman S, Richardson PG, Bladé J. Rosiñol L, et al. Among authors: vanderkerken k. Br J Haematol. 2021 Aug;194(3):496-507. doi: 10.1111/bjh.17338. Epub 2021 Mar 16. Br J Haematol. 2021. PMID: 33724461 Free article. Review.
Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment.
Egan H, Treacy O, Lynch K, Leonard NA, O'Malley G, Reidy E, O'Neill A, Corry SM, De Veirman K, Vanderkerken K, Egan LJ, Ritter T, Hogan AM, Redmond K, Peng L, Che J, Gatlin W, Jayaraman P, Sheehan M, Canney A, Hynes SO, Kerr EM, Dunne PD, O'Dwyer ME, Ryan AE. Egan H, et al. Among authors: vanderkerken k. Cell Rep. 2023 May 30;42(5):112475. doi: 10.1016/j.celrep.2023.112475. Epub 2023 May 10. Cell Rep. 2023. PMID: 37167967 Free article.
Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential.
Maes K, Mondino A, Lasarte JJ, Agirre X, Vanderkerken K, Prosper F, Breckpot K. Maes K, et al. Among authors: vanderkerken k. Front Immunol. 2021 Mar 30;12:652160. doi: 10.3389/fimmu.2021.652160. eCollection 2021. Front Immunol. 2021. PMID: 33859645 Free PMC article. Review.
Exosomes in multiple myeloma: from bench to bedside.
Menu E, Vanderkerken K. Menu E, et al. Among authors: vanderkerken k. Blood. 2022 Dec 8;140(23):2429-2442. doi: 10.1182/blood.2021014749. Blood. 2022. PMID: 35271699 Free PMC article. Review.
Targeting S100A9 protein affects mTOR-ER stress signaling and increases venetoclax sensitivity in Acute Myeloid Leukemia.
Fan R, Satilmis H, Vandewalle N, Verheye E, De Bruyne E, Menu E, De Beule N, De Becker A, Ates G, Massie A, Kerre T, Törngren M, Eriksson H, Vanderkerken K, Breckpot K, Maes K, De Veirman K. Fan R, et al. Among authors: vanderkerken k. Blood Cancer J. 2023 Dec 18;13(1):188. doi: 10.1038/s41408-023-00962-z. Blood Cancer J. 2023. PMID: 38110349 Free PMC article.
187 results